Several hepatitis A outbreaks have occurred in recent years. Although vaccines exist, effective antivirals against hepatitis A virus (HAV) are lacking, and knowledge gaps remain regarding the viral replication cycle.

Genmab and BioNTech have expanded their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer. Under the expansion, Genmab and BioNTech will jointly work to research, develop and commercialize novel monospecific antibody candidates for various cancer indications.

In HIV research, scientists are directing their efforts in several directions, attempting to prevent the infection, develop a vaccine, stop infection with the HIV virus progressing to AIDS, and eliminating reservoirs of dormant virus.

BriaCell Therapeutics has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize soluble CD80 (sCD80) as a biologic agent for the treatment of cancer.

Beta-site APP-cleaving enzyme 1 (BACE1) inhibitors have a long history of failure in patients with Alzheimer's disease (AD). Clinical development of verubecestat, elenbecestat, lanabecestat, umibecestat, atabecestat and LY-3202626 were all discontinued.

Post-traumatic OA (PTOA) is a specific type of osteoarthritis (OA) caused by injury. Both OA and PTOA are caused by an imbalance in catabolic and anabolic processes in articular cartilage as well as proinflammatory changes throughout the joint, which lead to joint degeneration and pain.

Scientists from the University of Washington and the Fred Hutchinson Cancer Research Center and their collaborators have described the generation of self-assembling nanoparticles displaying the Epstein-Barr virus (EBV) gH/gL glycoprotein complex as potential EBV vaccines.

Researchers from APIE Therapeutics presented preclinical data for the novel apelin receptor (APJ) agonist, APT-101, being developed as a small-molecule antifibrotic and anti-inflammatory agent.

Servier and Vernalis Group have divulged new spirocyclohexane derivatives acting as induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors and apoptosis inducers reported to be useful for the treatment of cancer, immunological disorders and autoimmune diseases.

After stroke, chondroitin sulfate proteoglycans (CSPGs) inhibit neuroblast migration and axon sprouting, but these effects can be blunted by modulating receptor-type tyrosine-protein phosphatase S (PTPsigma).